# Panoquell-CA1: Injectable Pancreatitis Drug for Dogs Panoquell-CA1 is a prescription injectable medication for dogs with acute onset pancreatitis. Its active ingredient is fuzapladib sodium, a leukocyte function-associated antigen type-1 (LFA-1) activation inhibitor. It is given by intravenous injection once daily for three days in a veterinary hospital setting. Panoquell-CA1 is a targeted anti-inflammatory treatment that works alongside standard supportive care. It does not replace intravenous fluids, pain control, antiemetics, or nutritional support, which remain the foundation of pancreatitis management [1][2]. This article explains what fuzapladib does, how it is given, what monitoring matters during and after treatment, and where the drug fits among the other tools veterinarians use for acute [pancreatitis in dogs](/knowledge/veterinary-medicine/clinical-methods/pancreatitis-in-dogs). ## At a Glance | Feature | Detail | |--|--| | Active ingredient | Fuzapladib sodium | | Drug class | Leukocyte function-associated antigen type-1 (LFA-1) activation inhibitor | | Species | Dogs | | Labeled indication | Clinical signs of acute onset pancreatitis | | Route | Intravenous injection | | Frequency | Once daily | | Duration | Three days | | Onset of measurable clinical response | Assessed at Day 3 in the pivotal study | | Prescription status | Prescription only, administered by a veterinarian | | Regulatory status in the US | Conditional approval by the FDA | | Licensed in Japan | Yes, for clinical signs of acute onset pancreatitis | | Not a substitute for | Fluids, analgesia, antiemetics, nutritional support | ## What Panoquell-CA1 Is and What It Treats Panoquell-CA1 is the brand name for fuzapladib sodium, the first pharmaceutical agent developed specifically to modify the inflammatory cascade in canine acute onset pancreatitis rather than only treating its symptoms [2]. Before fuzapladib, management of acute pancreatitis in dogs relied almost entirely on supportive and symptomatic care. That care is still essential, but fuzapladib adds a targeted anti-inflammatory mechanism aimed at the neutrophil-driven component of the disease [1][2]. The labeled indication is the treatment of clinical signs of acute onset pancreatitis in dogs. It is not a treatment for chronic pancreatitis, and it is not approved for use in cats. The clinical evidence base comes from dogs with presumptive acute onset pancreatitis, meaning the diagnosis was made on the combination of history, physical examination, and laboratory findings consistent with the disease rather than on pancreatic biopsy [1]. Acute onset pancreatitis in dogs is common and presents both diagnostic and management challenges. Most cases are considered idiopathic, meaning no single cause is identified. Fluid therapy tailored to the individual patient, antiemetics to control vomiting and fluid loss, analgesics for abdominal pain, early nutritional support, and recognition of complications form the core of management [2]. Fuzapladib sits on top of that framework, not in place of it. ## How Fuzapladib Sodium Works ### The LFA-1 Mechanism Fuzapladib sodium is a leukocyte function-associated antigen type-1 activation inhibitor. LFA-1 is an adhesion molecule on the surface of leukocytes, particularly neutrophils. When LFA-1 is activated, neutrophils become sticky and migrate out of the bloodstream into tissue. In pancreatitis, that migration into and around the pancreas is part of the inflammatory injury that can drive the disease forward and spill into systemic inflammation [1]. By blocking LFA-1 activation, fuzapladib interferes with the activation, adhesion, and migration of neutrophils. The intended result is a reduction in the neutrophil-driven inflammatory amplification that can worsen pancreatic injury and contribute to systemic complications. The rationale is that dampening this specific step of the inflammatory response may decrease the risk of pancreatitis progression and systemic inflammation [1]. This is a targeted mechanism, not broad immunosuppression. It acts on a specific adhesion pathway rather than suppressing the immune system globally, which is one reason it can be layered onto standard supportive care. ### Why the Inflammatory Cascade Matters Pancreatitis in dogs is understood through a balance between stressors and protective mechanisms, sometimes described using a critical threshold model. When stressors overwhelm the pancreas's protective capacity, clinical disease develops. Advances in understanding the pathophysiology have pointed to specific points in the inflammatory cascade that can be manipulated therapeutically, and LFA-1 activation is one of those points [3]. The neutrophil is a central actor in that cascade. After initial pancreatic injury, neutrophils are recruited to the area, and their adhesion and migration amplify tissue damage. Blocking LFA-1 activation interrupts that recruitment step. This is the biological basis for using fuzapladib early in an acute episode, when the inflammatory response is active and potentially still escalating. ## The Clinical Evidence ### The Pivotal Randomized Controlled Study The key study of fuzapladib was a randomized, masked, placebo-controlled multicenter trial in 61 client-owned dogs with presumptive acute onset pancreatitis. Sixty-one dogs were included in the safety assessment, and 35 evaluable cases were included in the clinical evaluation (fuzapladib, n = 16, placebo, n = 19). All dogs received standard of care, and the study compared fuzapladib plus standard of care against placebo plus standard of care [1]. Clinical improvement was measured using the change in the modified clinical activity index (MCAI) score on Day 3 compared with Day 0. The mean change in MCAI score was significantly higher in the fuzapladib-treated group (-7.75) than in the placebo group (-5.68), with a P value of .02. A larger negative change represents greater clinical improvement. Secondary variables included the canine acute pancreatitis clinical severity index (CAPCSI) scores and serum concentrations of canine pancreatic lipase immunoreactivity, cytokines, and C-reactive protein [1]. Fuzapladib was well tolerated by all treated dogs in the study [1]. ### What the Evidence Does and Does Not Show The study supports a reasonable expectation of effectiveness for fuzapladib as an addition to standard of care in dogs with acute onset pancreatitis [2]. The primary endpoint was a clinical activity index measured at Day 3, which reflects how the dogs were doing clinically after the three-day course. The study was not designed to prove a mortality benefit, and it did not establish a survival advantage. The published record includes scientific correspondence about the trial, including a letter raising points about the study and a published response from the authors [4][5]. This kind of exchange is normal in veterinary clinical research and reflects ongoing scrutiny of the evidence. For owners, the practical takeaway is that fuzapladib is a supportive anti-inflammatory treatment with demonstrated clinical improvement over standard of care alone in a controlled study, not a cure and not a replacement for intensive supportive management. ## How Panoquell-CA1 Is Given Panoquell-CA1 is administered as an intravenous injection once daily for three consecutive days [1]. Because it is an intravenous prescription product given in a hospital, the veterinary team handles preparation and administration. Owners do not give this medication at home. The three-day course is designed to cover the early, active phase of an acute pancreatitis episode, when the inflammatory cascade is most active. The clinical response in the pivotal study was assessed at the end of that three-day course [1]. Dosing is determined by the veterinarian according to the product label and the individual dog's weight and clinical status. This article does not provide a dose. Dose information belongs on the product label and in the hands of the treating veterinarian, who can account for the dog's weight, hydration, kidney function, and concurrent treatments. ### What Panoquell-CA1 Does Not Replace Fuzapladib is an addition to standard of care, not a substitute for any part of it. In the pivotal study, every dog received standard of care, and fuzapladib was compared against placebo on top of that baseline [1]. The components of standard of care that owners should expect include: - **Fluid therapy** tailored to the patient's needs, to restore and maintain hydration without overhydrating [2] - **Antiemetics** to control vomiting and fluid loss and to support early nutritional support [2] - **Analgesia** for abdominal pain, which is a major welfare concern in acute pancreatitis [2] - **Nutritional support**, started early, because vomiting and anorexia are common and nutrition is central to recovery [2][6] - **Complication management**, including recognition and treatment of problems that arise during the episode [2] Antibiotics are not given indiscriminately in pancreatitis. They are indicated when there is aspiration pneumonia, gastrointestinal bacterial translocation, or evidence of another bacterial infection. Proton pump inhibitors and plasma are not routinely prescribed unless specifically indicated [2]. ## The Treatment Workflow The diagram below shows the main path from presentation through treatment and monitoring for a dog receiving Panoquell-CA1. ```mermaid flowchart TD A[Dog presents with acute onset pancreatitis] --> B[Veterinarian confirms diagnosis and severity] B --> C[Standard of care begins] C --> D[Fluids analgesia antiemetics nutrition] D --> E[Fuzapladib given intravenously once daily] E --> F[Day 1 dose] F --> G[Day 2 dose] G --> H[Day 3 dose] H --> I[Reassess clinical activity and pain] I --> J[Continue supportive care as needed] J --> K[Plan recheck and home monitoring] ``` ## Monitoring During and After Treatment Monitoring in acute pancreatitis is about tracking severity, hydration, vomiting, and pain. These four domains drive most treatment decisions during the three-day course and afterward. ### Severity Veterinarians use structured clinical scoring to track how sick a dog is and whether it is improving. The modified clinical activity index (MCAI) and the canine acute pancreatitis clinical severity index (CAPCSI) are the tools used in the fuzapladib study to measure clinical status and severity [1]. Owners will not calculate these scores, but they should expect the veterinary team to reassess the dog's overall clinical picture each day, including attitude, appetite, hydration, abdominal comfort, and laboratory trends. ### Hydration Fluid therapy must be tailored to the individual patient to provide adequate hydration while preventing overhydration [2]. Monitoring hydration means watching for signs of both dehydration and fluid overload. The veterinary team assesses this through physical examination, body weight, and where indicated, laboratory values. Owners can help by reporting how much the dog is drinking and urinating, and any changes in gum moisture or skin elasticity at home after discharge. ### Vomiting Antiemetics are required to control vomiting and fluid loss and to aid in early nutritional support [2]. Monitoring vomiting means tracking frequency, volume, and whether the dog can keep down food or water. Persistent vomiting despite antiemetics is a reason to contact the veterinarian, because it can worsen dehydration and delay nutritional recovery. ### Pain Analgesics for abdominal pain are very important in acute pancreatitis [2]. Pain in dogs can look like restlessness, a tucked abdomen, reluctance to lie down comfortably, panting, or a reluctance to eat. Owners should report any signs of discomfort, because pain control is a core part of care and can be adjusted. ### Other Parameters The study also measured serum concentrations of canine pancreatic lipase immunoreactivity, cytokines, and C-reactive protein as secondary variables [1]. These are laboratory markers a veterinarian may use to track the inflammatory and pancreatic picture. They are interpreted alongside the clinical examination, not in isolation. | Domain | What is tracked | Why it matters | |--|--|--| | Severity | Clinical activity and severity scores, attitude, appetite | Shows whether the dog is improving or worsening | | Hydration | Fluid balance, body weight, physical exam | Prevents dehydration and overhydration | | Vomiting | Frequency, volume, tolerance of food and water | Protects hydration and supports nutrition | | Pain | Abdominal comfort, posture, behavior | Pain control is a core part of care | | Laboratory | Pancreatic lipase, CRP, cytokines where used | Supports the overall clinical picture | ## Side Effects and What to Do About Them Fuzapladib was well tolerated by all treated dogs in the pivotal study [1]. That is reassuring, but it does not mean side effects are impossible in every dog. Because the drug is given intravenously in a hospital, the veterinary team can observe the dog directly during and after each dose. Owners should report any change in their dog's condition during the treatment period, including: - Worsening vomiting or inability to keep down food or water - Signs of abdominal pain such as restlessness, panting, or a tucked abdomen - Lethargy or a change in mentation - Changes in drinking or urination - Any reaction noticed around the time of an injection Because the three-day course is given in hospital, most reactions would be seen by staff. After discharge, owners become the observers. Any deterioration at home warrants a call to the veterinarian. ## Which Dogs Should Not Receive Panoquell-CA1 Panoquell-CA1 is for dogs with acute onset pancreatitis. It is not for cats, and it is not for chronic pancreatitis. The clinical evidence and the labeled indication are specific to acute onset disease in dogs [1][2]. The treating veterinarian decides whether an individual dog is a suitable candidate. Factors that can affect that decision include the dog's overall clinical status, hydration, kidney function, concurrent medications, and whether the diagnosis is truly acute onset pancreatitis rather than another condition that can mimic it. Dogs with acute abdomen from other causes, such as a pancreatic mass, biliary obstruction, or gastrointestinal foreign body, need different diagnostics and treatments. Owners should give the veterinarian a complete list of medications and supplements the dog is receiving. This includes prescription drugs, over-the-counter products, and any supplements. The veterinarian can then assess for interactions and adjust the plan. ## How Panoquell-CA1 Compares With Other Options ### Standard Supportive Care Standard supportive care remains the backbone of acute pancreatitis treatment. It includes tailored fluid therapy, antiemetics, analgesia, early nutritional support, and complication management [2]. Fuzapladib is added to this foundation. It does not replace any element of it. ### Other Anti-Inflammatory Approaches Under Study Researchers continue to look for ways to modify the inflammatory response in [canine pancreatitis](/knowledge/veterinary-medicine/nutrition/canine-pancreatitis-symptoms-emergency-care-diet-management). One area under investigation is allogenic adipose-derived mesenchymal stem cell infusion. In a small pilot study, mesenchymal stem cells were given to dogs with acute pancreatitis, and no significant differences were found between treated dogs and [a control group](/blog/guides/understanding-control-groups-in-clinical-trials-types-and-selection) receiving standard of care for changes in Spec cPL, C-reactive protein, or MCAI. Subjective clinical improvements were noted within 24 hours in two dogs with previously refractory disease. The authors concluded that stem cell infusions appear safe in acute pancreatitis and may be considered in refractory disease, but that larger randomized controlled trials are needed [7]. This is an investigational approach, not a licensed product, and it is not a substitute for standard care. ### What Fuzapladib Adds Fuzapladib is the first specific therapeutic agent licensed for the treatment of clinical signs of acute onset pancreatitis in dogs, with licensure in Japan and conditional approval in the United States [2]. Its value is that it targets a defined step in the inflammatory cascade while standard care addresses hydration, vomiting, pain, and nutrition. The two approaches are complementary. ## Questions to Ask Your Veterinarian Owners facing a pancreatitis diagnosis for their dog may want to ask: 1. Does my dog have acute onset pancreatitis, and how confident are you in the diagnosis? 2. Is my dog a candidate for Panoquell-CA1, and why or why not? 3. What is the full supportive care plan, including fluids, antiemetics, pain control, and nutrition? 4. How will you monitor severity, hydration, vomiting, and pain during the three-day course? 5. What signs at home should prompt me to call you immediately? 6. What is the expected timeline for improvement, and what happens if my dog does not improve? 7. Are there any medications or supplements my dog is taking that could interact with treatment? 8. What follow-up or recheck do you recommend after discharge? ## Limitations and When to Contact a Veterinarian Acute pancreatitis can worsen quickly, and every dog responds differently. Fuzapladib was well tolerated and showed greater clinical improvement than placebo on top of standard of care in a controlled study, but it is not a guarantee of recovery, and it does not replace intensive supportive management [1][2]. Individual cases require a veterinarian's assessment. Contact a veterinarian promptly if your dog shows any of the following: - Repeated vomiting or inability to keep down food or water - Signs of abdominal pain, including restlessness, panting, a tucked abdomen, or reluctance to move - Lethargy, weakness, or a change in responsiveness - Refusal to eat or drink for more than a short period - Signs of dehydration such as tacky gums or loss of skin elasticity - Any deterioration after discharge, including worsening of the signs that brought your dog in If your dog is hospitalized and receiving treatment, tell the veterinary team about any change you notice during visits or in updates. Early reporting helps the team adjust fluids, antiemetics, analgesia, and nutrition. ## Why Acute Pancreatitis Is Hard to Diagnose in Dogs One of the reasons a targeted drug like Panoquell-CA1 matters is that acute pancreatitis is genuinely difficult to confirm. The pancreas sits deep in the abdomen, tucked against the duodenum and partly obscured by the stomach, intestines, and liver. It cannot be palpated directly in most dogs, and it cannot be biopsied safely in a dog that is already critically ill. This anatomical reality shapes the entire diagnostic workflow and explains why the pivotal fuzapladib study enrolled dogs with presumptive rather than biopsy-confirmed disease [1]. The clinical signs of acute pancreatitis are notoriously nonspecific. Vomiting, anorexia, lethargy, abdominal discomfort, and diarrhea can each point toward pancreatitis, but they can also point toward gastroenteritis, a gastrointestinal foreign body, biliary disease, or a dozen other conditions. Some dogs present with classic signs. Others present with vague malaise that an owner might attribute to a minor stomach upset. This variability is why veterinarians rely on a combination of history, physical examination, and laboratory testing rather than any single finding. The history itself carries diagnostic weight. A recent dietary indiscretion, a high-fat meal, or a scavenging episode is a common trigger story, though many dogs with pancreatitis have no such history. Certain breeds are overrepresented, and middle-aged to older dogs that are overweight or have concurrent endocrine disease appear more frequently in case series. None of these associations is strong enough to make a diagnosis on history alone, but together they raise or lower the index of suspicion. Physical examination findings are similarly variable. Some dogs have a painful abdomen on palpation. Others have a tense or tucked abdomen. Some are dehydrated with tacky mucous membranes. Others look surprisingly comfortable despite significant laboratory abnormalities. The veterinarian's job is to synthesize all of these signals into a working diagnosis and a severity assessment, then decide whether the dog is a candidate for targeted therapy like fuzapladib alongside standard supportive care [2]. ## The Diagnostic Workflow Step by Step Understanding the diagnostic process helps owners participate meaningfully in decisions about their dog's care. The workflow typically moves through several stages, and each stage informs the next. ### History and Physical Examination The first step is a thorough history. The veterinarian will ask about the timeline of signs, what the dog has eaten recently, whether there has been any access to garbage or high-fat food, whether the dog is on any medications that can predispose to pancreatitis, and whether there have been previous episodes. Previous episodes matter because recurrent acute pancreatitis can evolve into a chronic pattern, and the treatment approach differs. The physical examination focuses on hydration status, abdominal comfort, body condition, and signs of systemic illness such as pale mucous membranes, prolonged capillary refill time, or altered mentation. These findings help the veterinarian decide how aggressively to pursue diagnostics and how urgently to begin supportive care. ### Laboratory Testing Laboratory testing is where the diagnostic picture sharpens. A complete blood count can show changes consistent with inflammation or stress. A serum biochemistry panel assesses kidney function, liver enzymes, electrolytes, and glucose, all of which can be affected by pancreatitis or by concurrent disease. Electrolyte abnormalities are common and directly influence fluid therapy planning. Pancreatic lipase immunoreactivity, commonly measured as canine pancreatic lipase immunoreactivity or Spec cPL, is the most widely used pancreatic-specific blood test. It is more sensitive and specific than older tests like amylase and lipase, but it is not perfect. A normal result does not entirely rule out pancreatitis, and an elevated result does not by itself confirm it. The veterinarian interprets the result alongside the clinical picture. In the fuzapladib study, serum concentrations of canine pancreatic lipase immunoreactivity, cytokines, and C-reactive protein were measured as secondary variables, reflecting their role in characterizing the inflammatory state [1]. C-reactive protein is an acute phase protein that rises with systemic inflammation. It is not pancreas-specific, but it can help track the overall inflammatory burden and response to treatment. Cytokine measurements are primarily research tools at this stage, though they provide insight into the inflammatory pathways that fuzapladib is designed to modulate [1]. ### Imaging Abdominal ultrasound is the most useful imaging modality for suspected pancreatitis. It can reveal an enlarged, hypoechoic pancreas, surrounding fluid, or changes in adjacent structures. It can also identify alternative diagnoses such as a biliary obstruction, a pancreatic mass, or a gastrointestinal foreign body that would change the treatment plan entirely. Ultrasound findings can be subtle, and a normal-appearing pancreas on ultrasound does not exclude pancreatitis. Radiographs are less specific for pancreatitis but can help rule out other causes of acute abdomen, including obstruction or a perforated viscus. They are often part of the initial workup when the diagnosis is unclear. ### Severity Scoring Once a working diagnosis is established, the veterinarian assesses severity. Structured scoring systems like the modified clinical activity index and the canine acute pancreatitis clinical severity index provide a framework for tracking how sick the dog is and whether treatment is working [1]. These scores combine clinical parameters such as attitude, appetite, hydration, and abdominal comfort into a single number that can be compared over time. They are not a substitute for clinical judgment, but they help standardize assessment and communication between shifts and between veterinarians. Severity assessment drives decisions about hospitalization, the intensity of fluid therapy, the need for advanced pain management, and whether referral to a specialty center is warranted. A dog with mild disease may be managed with outpatient supportive care and close rechecks. A dog with severe disease may need intensive care, continuous monitoring, and management of systemic complications. ## Preparing for the Veterinary Visit Owners often arrive at the clinic worried and unsure what information will be useful. A little preparation can make the visit more efficient and improve the quality of the diagnostic process. ### Information to Bring The most valuable thing an owner can bring is a clear timeline. When did the signs start? What exactly has the dog been doing, and how has it changed over hours or days? Has the dog eaten anything unusual, and if so, when? Is the dog drinking and urinating normally? Has there been any vomiting, and if so, how many times and what did it look like? These details help the veterinarian narrow the differential list quickly. A complete medication and supplement list is essential. This includes prescription drugs, over-the-counter products, joint supplements, and any herbal or homeopathic products. Some medications and supplements can affect the pancreas, the liver, or the kidneys, and some can interact with treatments the veterinarian is considering. The veterinarian needs the full picture to make safe recommendations. Previous medical records are also valuable, especially if the dog has had prior episodes of pancreatitis or gastrointestinal disease. If the dog was seen at another clinic, having those records available saves time and prevents duplicate testing. ### Questions the Veterinarian Will Ask Owners can expect questions about diet, including the brand and type of food, whether table scraps or high-fat treats are given, and whether the dog has access to garbage or compost. They can expect questions about behavior changes, including whether the dog seems painful, restless, or unusually quiet. They can expect questions about urination and defecation, including color, consistency, and frequency. These questions are not busywork. Each answer contributes to the diagnostic picture and the treatment plan. ### What to Expect During the Visit The visit will likely include a physical examination, blood collection for laboratory testing, and possibly imaging. If pancreatitis is confirmed or strongly suspected, the veterinarian will discuss hospitalization, supportive care, and whether targeted therapy like Panoquell-CA1 is appropriate. Owners should feel free to ask about the reasoning behind each recommendation, the expected timeline for improvement, and the signs that should prompt an immediate call or return visit. ## Owner Observation During Recovery Once a dog is discharged from the hospital, the owner becomes the primary observer. Knowing what to watch for and what to report can make the difference between a smooth recovery and a setback. ### Appetite and Eating Appetite is one of the most useful recovery indicators. A dog that is interested in food and eating steadily is generally moving in the right direction. A dog that refuses food or eats only a few bites may still be nauseated or uncomfortable. Owners should track what the dog is offered, what it eats, and whether it keeps the food down. Any change in appetite should be reported to the veterinarian, especially if it persists for more than a day. ### Vomiting and Regurgitation Vomiting is common in acute pancreatitis and should improve with antiemetic treatment. Owners should note the frequency, the appearance of the vomit, and whether it is associated with eating or drinking. Regurgitation, which looks different from vomiting and involves food or fluid coming up without abdominal effort, can indicate a different problem such as esophageal disease. Distinguishing between the two helps the veterinarian interpret the signs correctly. ### Pain and Comfort Abdominal pain can be subtle at home. Owners should watch for restlessness, pacing, panting, a tucked abdomen, reluctance to lie down, reluctance to climb stairs, or a change in sleeping position. Some dogs become clingy or seek out unusual places to rest. Others become irritable when touched. Any of these signs warrants a call to the veterinarian, because pain control is a core part of pancreatitis management and can be adjusted [2]. ### Hydration and Urination Owners can monitor hydration by checking gum moisture, skin elasticity, and whether the dog is drinking normally. A dog that is drinking excessively may be compensating for fluid loss, or may have another problem such as kidney disease or diabetes. A dog that is not drinking at all is at risk of dehydration. Urination frequency and volume are also useful to track, especially if the dog is receiving fluid therapy at home or has concurrent kidney disease. ### Energy and Mentation Lethargy is expected during the acute phase of pancreatitis, but it should improve as the dog recovers. Owners should watch for a return of normal behavior, interest in surroundings, and responsiveness. A dog that becomes more lethargic, disoriented, or difficult to rouse needs immediate veterinary attention. ### What to Report Immediately Certain signs should prompt an immediate call to the veterinarian rather than a wait-and-see approach. These include repeated vomiting, inability to keep down food or water, signs of severe abdominal pain, collapse or weakness, difficulty breathing, seizures, or any rapid deterioration in the dog's condition. Early reporting allows the veterinary team to intervene before a setback becomes a crisis. ## Prevention and Risk Reduction Panoquell-CA1 treats an acute episode, but it does not prevent future episodes. Prevention is about reducing the risk factors that contribute to pancreatitis and recognizing early signs so that treatment can begin promptly. ### Dietary Management Diet is the most modifiable risk factor for many dogs. High-fat meals, table scraps, and scavenging are common triggers. Owners of dogs with a history of pancreatitis should work with their veterinarian to choose an appropriate diet, often one that is lower in fat and highly digestible. Treats should be chosen with the same care as the main diet. Sudden changes in diet should be avoided, and any transition should be gradual. ### Weight Management Obesity is associated with an increased risk of pancreatitis and with more severe disease. Maintaining a healthy body condition through portion control, appropriate exercise, and regular weight monitoring can reduce risk. Veterinarians can help owners assess body condition score and set realistic weight goals. ### Avoiding Known Triggers Some medications and supplements have been associated with pancreatitis in dogs. Owners should discuss any new medication or supplement with their veterinarian before starting it, especially in dogs with a history of pancreatic disease. Keeping dogs away from garbage, compost, and high-fat human foods is a simple but effective preventive measure. ### Recognizing Early Signs Early recognition is a form of prevention in the sense that prompt treatment can reduce the severity of an episode. Owners who know their dog's normal behavior can often detect subtle changes before the dog becomes seriously ill. A dog that is slightly quieter than usual, eating a little less, or showing mild abdominal discomfort may be in the early stages of an episode. Calling the veterinarian early can lead to earlier intervention and a better outcome. ### Regular Veterinary Care Routine wellness visits provide an opportunity to monitor weight, body condition, and laboratory values that can signal early problems. For dogs with a history of pancreatitis, more frequent monitoring may be appropriate. The veterinarian can track trends over time and adjust the preventive plan as needed. ## Prognosis and What Recovery Looks Like The prognosis for acute pancreatitis in dogs varies widely. Mild cases often recover with supportive care and may be managed on an outpatient basis. Severe cases can be life-threatening and may require intensive care, sometimes for several days. The presence of systemic complications such as shock, acute kidney injury, or respiratory compromise significantly affects the outlook. The fuzapladib study demonstrated greater clinical improvement at Day 3 in dogs receiving fuzapladib plus standard of care compared with placebo plus standard of care [1]. This supports the use of fuzapladib as part of a comprehensive treatment plan, but it does not predict the outcome for any individual dog. The study was not designed to show a mortality benefit, and it did not establish a survival advantage. Owners should understand that fuzapladib is one component of care, and that the overall prognosis depends on the severity of the episode, the dog's underlying health, and the response to supportive treatment. Recovery is often gradual. A dog may be discharged while still showing some signs, with instructions for home care and rechecks. Appetite and energy may take days to weeks to return to normal. Some dogs have lingering gastrointestinal sensitivity and need a bland or low-fat diet during recovery. Others recover fully and return to their normal routine. Recurrent episodes are possible, and owners should remain alert for early signs. ## Special Populations and Considerations Not every dog fits the profile of the typical patient in the pivotal study. Several populations deserve special consideration. ### Older Dogs Older dogs are more likely to have concurrent conditions such as kidney disease, heart disease, or endocrine disorders. These conditions affect fluid therapy planning, medication choices, and monitoring. The veterinarian will tailor the treatment plan to account for these factors. Older dogs may also have a slower recovery and may need more frequent rechecks. ### Dogs With Concurrent Disease Dogs with diabetes mellitus, hyperadrenocorticism, or hypothyroidism may be at increased risk of pancreatitis and may have a more complicated clinical course. Managing the concurrent disease is part of managing the pancreatitis. The veterinarian will consider how treatments for one condition affect the other and will adjust the plan accordingly. ### Dogs With Kidney or Liver Disease Kidney and liver function affect how the body handles fluids, medications, and metabolic waste. Dogs with impaired kidney or liver function may need adjusted fluid therapy and more intensive monitoring. The veterinarian will assess these organ systems as part of the diagnostic workup and will factor the results into the treatment plan. ### Dogs on Multiple Medications Polypharmacy increases the risk of interactions. Owners should provide a complete medication list, and the veterinarian should review it for potential interactions with fuzapladib and with other treatments. This is especially important for dogs receiving medications that affect the immune system, the kidneys, or the liver. ### Dogs With Recurrent Pancreatitis Dogs with recurrent episodes may have an underlying predisposing condition that has not been identified. The veterinarian may recommend additional diagnostics to look for chronic biliary disease, endocrine disorders, or other contributing factors. Management may include dietary changes, weight management, and avoidance of known triggers, in addition to treatment of acute episodes. ### Breeds and Genetic Predisposition Some breeds appear to be overrepresented in pancreatitis case series, suggesting a genetic or breed-related predisposition. Owners of these breeds should be aware of the signs and should seek veterinary care promptly if they appear. Breed predisposition does not change the treatment approach, but it may raise the index of suspicion during diagnosis. ## The Role of the Owner in the Treatment Team Owners are not passive observers in the management of acute pancreatitis. They provide history, monitor recovery, administer home care, and make decisions about treatment. Their observations often guide the veterinarian's decisions during and after hospitalization. The three-day course of Panoquell-CA1 is given in the hospital, but the owner's role begins before the first dose and continues long after the last. Owners who understand the disease, the treatment plan, and the signs to watch for are better equipped to participate in care and to recognize when something is going wrong. This article is intended to support that understanding, not to replace the veterinarian's assessment and recommendations. ## Evidence Limitations and Ongoing Questions The evidence base for fuzapladib is promising but limited. The pivotal study was a randomized, masked, placebo-controlled trial, which is a strong design for a veterinary clinical trial. However, it enrolled a relatively small number of dogs, and the primary endpoint was a clinical activity index at Day 3 rather than a long-term outcome such as survival or recurrence [1]. The study population was dogs with presumptive acute onset pancreatitis, which reflects real-world diagnosis but also introduces heterogeneity. The published scientific correspondence about the trial, including a letter raising points about the study and a published response from the authors, reflects the normal process of scientific scrutiny [4][5]. This kind of exchange is a sign of a healthy evidence base, not a sign that the drug is ineffective. It does mean that owners and veterinarians should interpret the evidence with appropriate humility. Several questions remain open. Does fuzapladib reduce the risk of recurrence? Does it improve long-term outcomes? Does it benefit specific subgroups more than others? Does it interact with other treatments in ways that have not yet been studied? These questions will be answered, if at all, by future research. In the meantime, the practical approach is to use fuzapladib as part of a comprehensive treatment plan, monitor the dog closely, and adjust care based on the individual response. ## Putting It All Together Panoquell-CA1 represents a meaningful step forward in the treatment of acute onset pancreatitis in dogs. It is the first pharmaceutical agent developed specifically to modify the inflammatory cascade in this disease, and it has demonstrated greater clinical improvement than placebo when added to standard of care in a controlled study [1][2]. It is given intravenously once daily for three days in a hospital setting, and it is well tolerated in the studied population. At the same time, it is not a cure and not a replacement for supportive care. Fluid therapy, antiemetics, analgesia, nutritional support, and complication management remain the foundation of treatment [2]. Owners should expect their veterinarian to use fuzapladib as one part of a broader plan, and they should participate actively in monitoring and decision-making. The best outcomes come from early recognition, prompt veterinary care, comprehensive supportive treatment, and attentive home monitoring. Owners who understand the disease and the treatment options are better prepared to help their dogs through an episode and to recognize when additional care is needed. This article is educational and is not a substitute for veterinary diagnosis or treatment. ## Frequently Asked Questions ### What is Panoquell-CA1 used for? Panoquell-CA1 is used to treat clinical signs of acute onset pancreatitis in dogs. Its active ingredient, fuzapladib sodium, is an LFA-1 activation inhibitor given alongside standard supportive care [1][2]. ### How is Panoquell-CA1 given? It is given as an intravenous injection once daily for three days in a veterinary hospital. Owners do not administer it at home [1]. ### Does Panoquell-CA1 replace fluids or pain medication? No. It is added to standard of care, which includes tailored fluid therapy, antiemetics, analgesia, and nutritional support. It does not replace any of these [1][2]. ### Can Panoquell-CA1 be used in cats? No. The labeled indication and the clinical evidence are for dogs with acute onset pancreatitis. It is not approved for cats [1][2]. ### Does Panoquell-CA1 treat chronic pancreatitis? No. It is indicated for clinical signs of acute onset pancreatitis. Chronic pancreatitis is a different clinical problem [1][2]. ### What side effects should I watch for? Fuzapladib was well tolerated in the pivotal study [1]. Report any worsening vomiting, abdominal pain, lethargy, or changes in drinking and urination to your veterinarian. ### How quickly should my dog improve? Clinical improvement in the pivotal study was assessed at Day 3 of treatment [1]. Your veterinarian will track your dog's progress daily and adjust supportive care as needed. ### What should I monitor at home after treatment? Watch for vomiting, abdominal pain, lethargy, and changes in appetite or drinking. Report any deterioration promptly to your veterinarian [2]. This article is educational and is not a substitute for veterinary diagnosis or treatment. ## Related Articles - [Bordetella Kennel Cough Vaccine: Oral vs Nasal vs Injectable Efficacy](/knowledge/veterinary-medicine/preventive-care/bordetella-kennel-cough-vaccine-oral-vs-nasal-vs-injectable-efficacy) - [Pancreatitis In Dogs](/knowledge/veterinary-medicine/clinical-methods/pancreatitis-in-dogs) - [Signs Of Pancreatitis In Dogs](/knowledge/veterinary-medicine/clinical-methods/signs-of-pancreatitis-in-dogs) - [Pancreatitis In Dogs Treatment](/knowledge/veterinary-medicine/clinical-methods/pancreatitis-in-dogs-treatment) - [Treatment Of Pancreatitis In Dogs Uk](/knowledge/veterinary-medicine/clinical-methods/treatment-of-pancreatitis-in-dogs-uk) - [Can Pancreatitis Be Cured In Dogs](/knowledge/veterinary-medicine/clinical-methods/can-pancreatitis-be-cured-in-dogs) - [Agonist vs Antagonist: Drug Receptor Actions Explained](/knowledge/veterinary-medicine/clinical-pharmacology/agonist-vs-antagonist-drug-receptor-actions-explained) - [Alpha-Adrenoceptor Blockers: Vet Drug Guide](/knowledge/veterinary-medicine/clinical-pharmacology/alpha-adrenoceptor-blockers-vet-drug-guide) - [Prokinetic Agents: Drug Classes and GI Uses](/knowledge/veterinary-medicine/clinical-pharmacology/prokinetic-agents-drug-classes-and-gi-uses) ## Sources 1. [Fuzapladib in a randomized controlled multicenter masked study in dogs with presumptive acute onset pancreatitis.](https://pubmed.ncbi.nlm.nih.gov/37811705/) 2. [Management of acute-onset pancreatitis in dogs: a Narrative Review.](https://pubmed.ncbi.nlm.nih.gov/38838711/) 3. [New insights into the etiology, risk factors, and pathogenesis of pancreatitis in dogs: Potential impacts on clinical practice.](https://pubmed.ncbi.nlm.nih.gov/35546513/) 4. [Response to letter regarding "Fuzapladib in a randomized controlled multicenter masked study in dogs with presumptive acute onset pancreatitis".](https://pubmed.ncbi.nlm.nih.gov/38471965/) 5. [Letter regarding "Fuzapladib in a randomized controlled multicenter masked study in dogs with presumptive acute onset pancreatitis".](https://pubmed.ncbi.nlm.nih.gov/38441383/) 6. [The Use of Diets in the Diagnosis and Treatment of Common Gastrointestinal Diseases in Dogs and Cats.](https://pubmed.ncbi.nlm.nih.gov/38625524/) 7. [Allogenic Adipose-Derived Mesenchymal Stem Cell Infusion for the Management of Acute-Onset Pancreatitis in Dogs: A Pilot Study.](https://pubmed.ncbi.nlm.nih.gov/39409854/)